News
Casey LCA Gene Therapy Treatment featured in the Oregonian
The Oregonian featured a Casey patient who was treated for Leber Congenital Amaurosis (LCA) as part of a clinical trial. LCA is the most common cause of inherited blindness in children, but this gene therapy clinical trial offers new hope.
Seattle Times Features Gene Therapy Patient
Two Seattle-area brothers were treated for Leber Congential Amaurosis (LCA) as part of the LCA Gene Therapy trial at Casey Eye Institute.
Casey Eye Institute is a leader in eye care. To share knowledge about new and emerging treatments with the eye care community, we publish a newsletter, In Full View, two times a year.
Download the Fall 2011 edition
The Macular Degeneration Center at Casey Eye Institute, OHSU, publishes InSight, a newsletter about new developments in treating and living with this condition. Macular degeneration is the leading cause of vision loss and blindness in the United States.
Download the latest Macular Degeneration Center newsletter